Key result
The polio eradication program faces endgame challenges including budget constraints, switching from oral to inactivated vaccines, and increased biosecurity requirements, which are being addressed by ongoing research.
This review highlights the challenges and research responses in the endgame of the Global Polio Eradication Initiative.
Endgame challenges persist in polio eradication; leaves open whether ongoing research will resolve budget, vaccine, and biosecurity issues.
Since the beginning of Global Polio Eradication Initiative in 1988, poliomyelitis cases caused by wild poliovirus (PV) have been drastically reduced, with only 74 cases reported in 2 endemic countries in 2015. The current limited PV transmission suggests that we are in the endgame of the polio eradication program. However, specific challenges have emerged in the endgame, including tight budget, switching of the vaccines, and changes in biorisk management of PV. To overcome these challenges, several PV studies have been implemented in the eradication program. Some of the responses to the emerging challenges in the polio endgame might be valuable in other infectious diseases eradication programs. Here, I will review challenges that confront the polio eradication program and current research to address these challenges.
No takes yet. Share an insight, caveat, or question.
Minetaro Arita (2016) conducted a review in Poliomyelitis. Poliovirus eradication strategies was evaluated. The polio eradication program faces endgame challenges including budget constraints, switching from oral to inactivated vaccines, and increased biosecurity requirements, which are being addressed by ongoing research.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: